

# Drug Master File Procedures in the EU, the US and Japan

Taking into account the guidance on elemental (ICH Q3D) and genotoxic (ICH M7) impurities

## Speakers



**Marieke van Dalen**  
Aspen Oss B.V.,  
The Netherlands




**Dr Hiltrud Horn**  
Horn Pharmaceutical  
Consulting, Germany



**Dr Usfeya A Muazzam**  
Bonn, Germany



**Dr Wilhelm Schlumbohm**  
Berlin, Germany



**17-18 September 2019, Copenhagen, Denmark**

## HIGHLIGHTS:

- Requirements of the European ASMF procedure
- Different types of Drug Master Files in the US
- How to document drug substance stability
- Compiling data for residual solvents and impurities taking into account metal and genotoxic impurities
- Special aspects of Drug Master Files in Japan
- Handling changes in European, US and Japanese Drug Master Files
- Maintaining Drug Master Files
- Comparison of ASMF and CEP procedure



---

# Drug Master File Procedures in the EU, the US and Japan

17-18 September 2019, Copenhagen, Denmark

---

## Objectives

This education course is intended to provide guidance on the procedures for the European ASMF, the US-DMF and the Japanese DMF. You will get to know

- how to describe manufacturing processes
- how to compile data for drug substance stability, impurities and residual solvents
- which are the important points to consider for US-DMFs
- which are the requirements for Japanese DMFs
- how to handle changes in European, US and Japanese DMFs
- which are the major differences and advantages of the ASMF and CEP procedure

Participants will have the opportunity to take part in one of two parallel workshops about

1. Description of the manufacturing process **or**
2. Managing changes in Drug Master Files

## Background

Documentation of the drug substance quality is an integral part of any marketing authorisation application. In Europe the most common document for this purpose is the Active Substance Master File (ASMF) as long as the applicant has no Certificate of Suitability of the pharmacopoeial monograph (CEP). The European ASMF procedure differs significantly from the US-DMF procedure and for strategic reasons it is very important to take these differences into account. Moreover, there are particular requirements for DMFs in Japan. For global acting companies it is a big challenge to handle the different procedures of compiling, submitting, changing and maintaining Drug Master Files in an efficient way.

## Target Audience

The education course is designed for all persons involved in the compilation of pharmaceutical dossiers for marketing authorisations, especially for Drug Master Files, who want to become familiar with the different DMF procedures. Furthermore, the course will be of interest to personnel from Quality Units of the pharmaceutical and the API industry.

---

## Programme

---

### The European Active Substance Master File procedure – An Introduction

- Regulatory background and Scope
- The revised ASMF guideline
- Open and closed parts – points to consider
- Comparison of ASMF and CEP procedure

### Drug Master File Procedures in the US

- Types of Drug Master Files
- Drug Master Files under GDUFA
- Submissions of DMFs
- Holder obligations
- Maintenance of Drug Master Files
- US vs EU DMF – differences in the procedure

### How to document drug substance stability

- Stability Guidelines
- Stability Testing of new drug substances and drug products
- Storage Conditions
- Bracketing and Matrixing Designs
- Stability data from new drug dosage forms
- How to document evaluation of stability data
- Optimising the submission

### Residual solvents and Impurities: synthesis derived Impurities, Metals and genotoxic Impurities

- Guidelines
- Impact of the new guidelines ICH Q3D and ICH M7
- Sources of Impurities
- Setting and justification of specifications
- Residual solvents, solvent classes
- Content and scope of data – documentation requirements
- Frequent mistakes

## Parallel Workshops

Please choose one out of two Parallel Workshops:

- **Description of the Active Substance manufacturing process**
- **Managing changes in Drug Master Files -Case Studies-**

### Post Approval Changes in the US

- Post approval activities
- Reporting requirements to the FDA (CBE 0, CBE 30, Annual Report)
- Post approval commitments and post approval reporting requirements
- Risk evaluation and mitigation strategies (REMS)

### Handling Changes in European Drug Master Files

- Why is there a need for changes
- Types of changes
- How to communicate with the MA holders and how to get feed back
- Differences between ASMF and CEP
- When to implement a specific change
- Version management of the ASMF

### Requirements of the Drug Master File Procedure in Japan

- Regulatory procedures in Japan:
  - Site accreditation | GMP paper-based inspection | Drug Master File
- Drug Master File format
- Specific points to consider for the J-DMF
- Communication with the Japanese authorities

### Changes and Maintenance of Japanese Drug Master Files

- Change procedures and communication with the Japanese authority
- Types of changes
- Notification of changes

### Comparison of the CEP and ASMF Procedure

- The certification scheme of the PhEur
- Advantages and disadvantages of the CEP procedure compared to the ASMF procedure
- Handling of variations in the CEP procedure
- Countries accepting CEPs

## Speakers



### Marieke van Dalen, Aspen Oss B.V., The Netherlands

Marieke van Dalen is the global regulatory specialist in the regulatory group dedicated to APIs, with almost 30 years of experience in the regulatory field. She is a board member of APIC, the European API Industry organization, and she participates in the Japan task force, Emerging markets task force and the Quality metrics task force. She frequently represents APIC in meetings and conferences organized by EMA, EDQM, ICH etc.



### Dr Hiltrud Horn, Managing Director of Horn Pharmaceutical Consulting, Germany

Dr Hiltrud Horn is managing director of HORN Pharmaceutical Consulting with focus on CMC, GMP and Regulatory Affairs (EU and US). She started in pharma industry in 1990 and held several managerial positions within Hoffmann-La Roche in Basel and Knoll (now Abbott) in Ludwigshafen with global responsibility within QC/QA/Regulatory Affairs / Project Management / Medical Writing. She was consultant for the biotech and life science industry at Cap Gemini Ernst & Young prior to starting her own business more than 13 years ago. She is pharmacist with a Ph.D. and holds a Diploma in Pharmaceutical Medicine (Basel). Furthermore she is specialised pharmacist for pharmaceutical analytics and for drug information.



### Dr Usfeya A. Muazzam, Bonn, Germany

Dr Usfeya A. Muazzam worked as Senior Assessor for Quality, Division: Quality, Department: Scientific Quality Assurance, Staff Unit: Strategy and Planning of BfArM. He left the agency in 2012. He is co-author of "Gute Regulatorische Praxis, Arzneimittelzulassung - Pharmazeutische Qualität", Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany and "Guide to Drug Regulatory Affairs", Editio Cantor Verlag, Aulendorf, Germany.



### Dr Wilhelm Schlumbohm, Berlin, Germany

Dr Schlumbohm worked more than 25 years with German drug licensing authorities in the field of assessment of the CMC parts of new drug applications. He is a member of the Working Group on Active Substance Master File procedures.

## Easy Registration



Reservation Form:  
CONCEPT HEIDELBERG  
P.O. Box 10 17 64  
69007 Heidelberg, Germany



Reservation Form:  
+ 49 6221 84 44 34



e-mail:  
info@concept-heidelberg.de



Internet:  
www.gmp-compliance.org

### Date

Tuesday, 17 September 2019, 9.00 h– 17.45 h  
(Registration and coffee 8.30 h – 9.00)  
Wednesday, 18 September 2019, 8.30 h– 15.15 h

### Venue

Radisson Blu Scandinavia Hotel  
Amager Boulevard 70  
2300 Copenhagen S, Denmark  
Phone +45 (0)33 96 50 00  
Fax +45 (0)33 96 55 00  
Scandinavia.meetings.events@radissonblu.com

### Fees (per delegate plus VAT)

ECA Members € 1,590  
APIC Members € 1,690  
Non-ECA Members € 1,790  
EU GMP Inspectorates € 895  
The conference fee is payable in advance after receipt of invoice and includes conference documentation, dinner on the first day, lunch on both days and all refreshments. VAT is reclaimable.

### Accommodation

CONCEPT HEIDELBERG has reserved a limited number of rooms in the conference hotel. You will receive a room reservation form/POG when you have registered for the conference. Please use this form for your room reservation to receive the specially negotiated rate for the duration of your stay. Reservation should be made directly with the hotel. Early reservation is recommended.

### Conference language

The official conference language will be English.

### Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event.

CONCEPT HEIDELBERG  
P.O. Box 10 17 64  
D-69007 Heidelberg, Germany  
Phone +49 (0) 62 21/84 44-0  
Fax +49 (0) 62 21/84 44 34  
E-mail: info@concept-heidelberg.de  
www.concept-heidelberg.de

### For questions regarding content please contact:

Dr Gerhard Becker (Operations Director) at +49-62 21/84 44 65  
or per e-mail at becker@concept-heidelberg.de.

### For questions regarding reservation, hotel, organisation etc. please contact:

Ms Susanne Ludwig (Organisation Manager) at +49-62 21/84 44 44, or  
per e-mail at ludwig@concept-heidelberg.de.



### Social Event

In the evening of the first conference day, you are cordially invited to a social event. This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere.

If the bill-to-address deviates from the specification to the right, please fill out here:

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

CONCEPT HEIDELBERG  
P.O. Box 10 17 64  
Fax +49 (0) 6221/84 44 34

69007 Heidelberg  
Germany

### Reservation Form (Please complete in full)

+49 6221 84 44 34

### Drug Master File Procedures in the EU, the US and Japan

17-18 September 2019, Copenhagen, Denmark

Please choose ONE workshop:

- Description of the manufacturing process  
 Managing changes in Drug Master Files -Case Studies-

Mr  Ms

Title, first name, surname

Company

Department

**Important: Please indicate your company's VAT ID Number**

**Purchase Order Number, if applicable**

Street / P.O. Box

City

Zip Code

Country

Phone / Fax

E-Mail (Please fill in)

### General terms and conditions

If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.

2. If you have to cancel entirely we must charge the following processing fees: Cancellation

- until 2 weeks prior to the conference 10 %
- until 1 weeks prior to the conference 50 %
- within 1 week prior to the conference 100 %.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice

or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

**Terms of payment:** Payable without deductions within 10 days after receipt of invoice.

**Important:** This is a binding registration and above fees are due in case of cancellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be

calculated according to the point of time at which we receive your message. In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed)! (As of January 2012).

**Privacy Policy:** By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal

data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at [http://www.gmp-compliance.org/eca\\_privacy.html](http://www.gmp-compliance.org/eca_privacy.html)). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website. German law shall apply. Court of jurisdiction is Heidelberg.